Company intelligence / Profile preview

Chronogen Inc.

Montréal, QC, Canadachronogen.com ↗
Ownership
Private
Development stage
Other
01

Overview

Chronogen Inc. is developing innovative small-molecule drugs targeting oxidative stress and lipid disorders associated with age-related conditions such as neurological and cardiovascular diseases. The company has established proprietary in vivo assays for identifying relevant drug targets. As of the latest available updates, their programs were advancing through preclinical and early clinical development stages.

Therapeutic areas
OtherCardiovascularNeurology
Modalities
Small molecules
Industry
Biotech
02

Drug pipeline

1 asset

CHGN111

Unknown

Beyond the preview

Go deeper on Chronogen Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chronogen Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call